302963-98-0

Basic information

• Product Name: 5-Thiazolecarboxylic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-phenyl-, ethyl ester
• Synonyms: 2-tert-Butoxycarbonylamino-4-phenyl-thiazole-5-carboxylic acid ethyl ester;ethyl-2-tert-butoxycarbonyloxyamino-4-phenyl-thiazole-5-carboxylate
• CAS NO: 302963-98-0
• Molecular Formula: C17H20N2O4S
• Molecular Weight: 348.423
• Mol File: 302963-98-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-Thiazolecarboxylic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-phenyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Thiazolecarboxylic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-phenyl-, ethyl ester(302963-98-0)
• EPA Substance Registry System: 5-Thiazolecarboxylic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-4-phenyl-, ethyl ester(302963-98-0)

Safety Data

• Hazardous Substances Data: 302963-98-0(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 64399-23-1 ethyl 4-phenyl-2-aminothiazole-5-carboxylate 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 302963-99-1 2-[[(tert-butyloxy)carbonyl]-amino]-4-phenyl-1,3-thiazole-5-carboxylic acid 
• 302964-00-7 2-tert-butoxycarbonyloxyamino-4-phenyl-thiazole-5-carboxylic acid chloride 
• 302957-89-7 [5-[[(2,4,6-trimethylphenyl)amino]carbonyl]-4-phenyl-2-thiazolyl]carbamic acid, 1,1-dimethylethyl ester 
• 881028-34-8 [5-(3-methyl-[1,2,4]oxadiazol-5-yl)-4-phenyl-thiazol-2-yl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays

Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. It is caused by different mutations in the cystic fibrosis transmembrane regulator protein (CFTR) gene, with F508del being the most common. During the last y

Cyclic protein tyrosine kinase inhibitors

Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.